Guardant Health Stock

Guardant Health P/S 2024

Guardant Health P/S

4.29

Ticker

GH

ISIN

US40131M1099

WKN

A2N5RY

As of Sep 11, 2024, Guardant Health's P/S ratio stood at 4.29, a -31.14% change from the 6.23 P/S ratio recorded in the previous year.

The Guardant Health P/S history

Guardant Health Aktienanalyse

What does Guardant Health do?

Guardant Health Inc is an American company specializing in the development of non-invasive diagnostic tests for cancer. The company was founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz. The two founders had previously successfully founded a company specialized in the development of blood tests for pregnancies. Guardant Health's goal is to detect traces of cancer cells in the blood of patients to enable early cancer diagnosis. Based on the liquid biopsy tests offered by the company, doctors can identify tumor cells and genetic mutations without relying on invasive methods such as tissue sampling. This allows for faster diagnosis and quicker treatment decision-making. Guardant Health's business model is based on the commercialization of its liquid biopsy tests, which are based on specially developed DNA sequencing methods. The company offers both diagnostic tests that can aid in cancer identification, as well as tests that can help doctors monitor the success of cancer therapies. Guardant Health has directed its offerings towards multiple products and divisions, including Guardant360, GuardantOmni, and GuardantReveal. Each of these products aims to solve specific challenges related to cancer diagnosis and treatment. Guardant360 is a diagnostic test specifically developed to help doctors sequence the DNA of cancer cells in the blood of patients and identify the genetic changes contributing to tumor growth. On the other hand, GuardantOmni is a liquid biopsy test that targets a broader range of cancer types. It enables a comprehensive genetic scan of cancer cells in the blood to identify specific mutations that can aid in tracking disease progression and selecting appropriate therapies. GuardantReveal is a test aimed at monitoring patients at higher risk of cancer. The test can be used to detect early signs of tumors in patients who are at higher risk due to their family history, age, or other factors. Guardant Health has achieved considerable success in the field of liquid biopsy detection in recent years. Currently, more than 100,000 patients worldwide have access to Guardant Health's liquid biopsy-based tests. The company is based in Redwood City, California, and employs over 1,000 employees. It has a broad investor base, including The SoftBank Vision Fund, Sequoia Capital, Lightspeed Venture Partners, and Khosla Ventures. Overall, the company has raised over $550 million in funding. Guardant Health aims to revolutionize the world of cancer diagnostics and treatment. By radically changing the process of diagnosing and monitoring cancer patients, the company aims to improve the survival rate of cancer patients and make cancer treatment more effective overall. Guardant Health ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Guardant Health's P/S Ratio

Guardant Health's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Guardant Health's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Guardant Health's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Guardant Health’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Guardant Health stock

What is the price-to-earnings ratio of Guardant Health?

The price-earnings ratio of Guardant Health is currently 4.29.

How has the price-earnings ratio of Guardant Health changed compared to last year?

The price-to-earnings ratio of Guardant Health has increased by -31.14% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Guardant Health high compared to other companies?

Yes, the price-to-earnings ratio of Guardant Health is high compared to other companies.

How does an increase in the price-earnings ratio of Guardant Health affect the company?

An increase in the price-earnings ratio of Guardant Health would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Guardant Health affect the company?

A decrease in the price-earnings ratio of Guardant Health would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Guardant Health?

Some factors that influence the price-earnings ratio of Guardant Health are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Guardant Health pay?

Over the past 12 months, Guardant Health paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Guardant Health is expected to pay a dividend of 0 USD.

What is the dividend yield of Guardant Health?

The current dividend yield of Guardant Health is .

When does Guardant Health pay dividends?

Guardant Health pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Guardant Health?

Guardant Health paid dividends every year for the past 0 years.

What is the dividend of Guardant Health?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Guardant Health located?

Guardant Health is assigned to the 'Health' sector.

Wann musste ich die Aktien von Guardant Health kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Guardant Health from 9/11/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/11/2024.

When did Guardant Health pay the last dividend?

The last dividend was paid out on 9/11/2024.

What was the dividend of Guardant Health in the year 2023?

In the year 2023, Guardant Health distributed 0 USD as dividends.

In which currency does Guardant Health pay out the dividend?

The dividends of Guardant Health are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Guardant Health

Our stock analysis for Guardant Health Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Guardant Health Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.